{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.ai-analytics.org/api/v1/entity/NONOF/timeline","_source":{"data_provider":"AI Analytics","data_provider_url":"https://api.ai-analytics.org","license":"https://api.ai-analytics.org/license","usage_info":"https://api.ai-analytics.org/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-09-22T18:18:47.056Z","methodology_url":"https://api.ai-analytics.org/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":8164,"canonical_name":"NOVO NORDISK A S","cik":"0000353278","uei":null,"lei":null,"duns":null,"ticker":"NONOF"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","open.payments","dol.form5500","hud.housing","irs.bmf"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":10,"clinical":58},"count":68,"timeline":[{"ts":"2026-07-21","kind":"sec.filing","form_type":"6-K","title":"6-K — NOVO NORDISK A S — 2026-07-21","url_slug":"/sec/cik-0000353278/6-k/0001171843-26-004788","accession_number":"0001171843-26-004788","importance":30},{"ts":"2026-07-06","kind":"sec.filing","form_type":"6-K","title":"6-K — NOVO NORDISK A S — 2026-07-06","url_slug":"/sec/cik-0000353278/6-k/0001171843-26-004469","accession_number":"0001171843-26-004469","importance":30},{"ts":"2026-06-29","kind":"sec.filing","form_type":"6-K","title":"6-K — NOVO NORDISK A S — 2026-06-29","url_slug":"/sec/cik-0000353278/6-k/0001171843-26-004353","accession_number":"0001171843-26-004353","importance":30},{"ts":"2026-06-22","kind":"sec.filing","form_type":"11-K","title":"11-K — NOVO NORDISK A S — 2026-06-22","url_slug":"/sec/cik-0000353278/11-k/0001171843-26-004204","accession_number":"0001171843-26-004204","importance":30},{"ts":"2026-06-22","kind":"sec.filing","form_type":"11-K","title":"11-K — NOVO NORDISK A S — 2026-06-22","url_slug":"/sec/cik-0000353278/11-k/0001171843-26-004205","accession_number":"0001171843-26-004205","importance":30},{"ts":"2026-06-15","kind":"sec.filing","form_type":"6-K","title":"6-K — NOVO NORDISK A S — 2026-06-15","url_slug":"/sec/cik-0000353278/6-k/0001171843-26-004116","accession_number":"0001171843-26-004116","importance":30},{"ts":"2026-06-08","kind":"sec.filing","form_type":"6-K","title":"6-K — NOVO NORDISK A S — 2026-06-08","url_slug":"/sec/cik-0000353278/6-k/0001171843-26-003963","accession_number":"0001171843-26-003963","importance":30},{"ts":"2026-05-18","kind":"clinical.trial","reporter":"Novo Nordisk A/S","title":"A Research Study to See How Well Semaglutide Helps People Who Have a Body Weight Above the Healthy Weight Range","security_title":"PHASE3","status":"COMPLETED","accession_number":"NCT06041217","excerpt":"[\"Overweight\",\"Obesity\"]","importance":70},{"ts":"2026-05-18","kind":"sec.filing","form_type":"6-K","title":"6-K — NOVO NORDISK A S — 2026-05-18","url_slug":"/sec/cik-0000353278/6-k/0001171843-26-003506","accession_number":"0001171843-26-003506","importance":30},{"ts":"2026-05-15","kind":"clinical.trial","reporter":"Novo Nordisk A/S","title":"AMAZE 6: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07509307","excerpt":"[\"Obesity\",\"Overweight\",\"Osteoarthritis, Knee\"]","importance":60},{"ts":"2026-05-15","kind":"clinical.trial","reporter":"Novo Nordisk A/S","title":"A Research Study Looking Into How Cagrilintide Influences Food Intake and Appetite in People With Overweight or Obesity","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT07557953","excerpt":"[\"Overweight\",\"Obesity\"]","importance":30},{"ts":"2026-05-14","kind":"clinical.trial","reporter":"Novo Nordisk A/S","title":"A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Knee Osteoarthritis Lose Weight and Reduce Pain","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07481630","excerpt":"[\"Obesity\",\"Knee Osteoarthritis (OA)\"]","importance":60},{"ts":"2026-05-14","kind":"clinical.trial","reporter":"Novo Nordisk A/S","title":"A Research Study Looking Into Blood Levels of the Medicine NNC0487-0111 in the Body and How Well it is Tolerated in People With Reduced Liver Function and Normal Liver Function","security_title":"PHASE1","status":"NOT_YET_RECRUITING","accession_number":"NCT07587710","excerpt":"[\"Overweight\",\"Obesity\"]","importance":30},{"ts":"2026-05-13","kind":"clinical.trial","reporter":"Novo Nordisk A/S","title":"AMAZE 1: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Lose Weight","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07339423","excerpt":"[\"Obesity\"]","importance":60},{"ts":"2026-05-13","kind":"sec.filing","form_type":"6-K","title":"6-K — NOVO NORDISK A S — 2026-05-13","url_slug":"/sec/cik-0000353278/6-k/0001171843-26-003349","accession_number":"0001171843-26-003349","importance":30},{"ts":"2026-05-11","kind":"clinical.trial","reporter":"Novo Nordisk A/S","title":"A Research Study Investigating the Effect of NNC0497-0040 in Healthy Participants, Participants With Overweight or Obesity, and Participants With Type 1 Diabetes With Overweight or Obesity","security_title":"PHASE1","status":"NOT_YET_RECRUITING","accession_number":"NCT07578584","excerpt":"[\"Type 1 Diabetes (T1D)\",\"Overweight\",\"Obesity\",\"Healthy Volunteers\"]","importance":30},{"ts":"2026-05-07","kind":"clinical.trial","reporter":"Novo Nordisk A/S","title":"A Research Study on How Well Different Doses of the Medicine NNC0662-0419 Help People Living With Overweight or Obesity","security_title":"PHASE2","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT07184632","excerpt":"[\"Overweight\",\"Obesity\"]","importance":45},{"ts":"2026-05-07","kind":"clinical.trial","reporter":"Novo Nordisk A/S","title":"Understanding the Effect of CagriSema, Cagrilintide, and Semaglutide on Muscle Health (Role of Amylin Signature in Muscle Health)","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT07527195","excerpt":"[\"Obesity\"]","importance":30},{"ts":"2026-05-06","kind":"clinical.trial","reporter":"Novo Nordisk A/S","title":"AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea","security_title":"PHASE3","status":"NOT_YET_RECRUITING","accession_number":"NCT07571109","excerpt":"[\"Obesity\",\"Overweight\",\"Obstructive Sleep Apnoea\"]","importance":60},{"ts":"2026-05-06","kind":"clinical.trial","reporter":"Novo Nordisk A/S","title":"AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea","security_title":"PHASE3","status":"NOT_YET_RECRUITING","accession_number":"NCT07571005","excerpt":"[\"Obesity\",\"Overweight\",\"Obstructive Sleep Apnoea\"]","importance":60},{"ts":"2026-05-05","kind":"clinical.trial","reporter":"Novo Nordisk A/S","title":"A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight","security_title":"PHASE3","status":"COMPLETED","accession_number":"NCT06388187","excerpt":"[\"Obesity\"]","importance":70},{"ts":"2026-05-05","kind":"clinical.trial","reporter":"Novo Nordisk A/S","title":"AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07503210","excerpt":"[\"Obesity\"]","importance":60},{"ts":"2026-05-05","kind":"clinical.trial","reporter":"Novo Nordisk A/S","title":"A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin, SGLT2 Inhibitor or Both","security_title":"PHASE3","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT06534411","excerpt":"[\"Diabetes Mellitus, Type 2\"]","importance":60},{"ts":"2026-05-05","kind":"clinical.trial","reporter":"Novo Nordisk A/S","title":"A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity","security_title":"PHASE3","status":"NOT_YET_RECRUITING","accession_number":"NCT07567001","excerpt":"[\"Obesity\",\"Heart Failure\"]","importance":60},{"ts":"2026-05-05","kind":"clinical.trial","reporter":"Novo Nordisk A/S","title":"A Research Study Investigating How a New Medicine NNC0113-5840 Works in People With Overweight or Obesity","security_title":"PHASE1","status":"NOT_YET_RECRUITING","accession_number":"NCT07566390","excerpt":"[\"Obesity\",\"Overweight\"]","importance":30},{"ts":"2026-05-04","kind":"clinical.trial","reporter":"Novo Nordisk A/S","title":"A Study Collecting Remote Data in People With an Overweight Condition or Obesity on a Weight Management Program","security_title":null,"status":"COMPLETED","accession_number":"NCT06805539","excerpt":"[\"Overweight, Obesity\"]","importance":25},{"ts":"2026-04-30","kind":"clinical.trial","reporter":"Novo Nordisk A/S","title":"A Study Using Flash Glucose Measurements for a New Once-weekly Insulin (Insulin Icodec) in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 9)","security_title":"PHASE3","status":"COMPLETED","accession_number":"NCT05823948","excerpt":"[\"Diabetes Mellitus, Type 2\"]","importance":70},{"ts":"2026-04-30","kind":"clinical.trial","reporter":"Novo Nordisk A/S","title":"A Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes","security_title":"PHASE3","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT03811561","excerpt":"[\"Diabetes Mellitus, Type 2\"]","importance":60},{"ts":"2026-04-29","kind":"clinical.trial","reporter":"Novo Nordisk A/S","title":"Special Use-results Surveillance on Long Term Use of Sogroya® in Children With Short Stature Due to Growth Hormone Deficiency Where Epiphysial Discs Are Not Closed","security_title":null,"status":"ENROLLING_BY_INVITATION","accession_number":"NCT06109935","excerpt":"[\"Growth Hormone Deficiency in Children\"]","importance":25},{"ts":"2026-04-27","kind":"clinical.trial","reporter":"Novo Nordisk A/S","title":"AMAZE 2: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Type 2 Diabetes Lose Weight","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07533175","excerpt":"[\"Diabetes Mellitus\",\"Overweight\",\"Obesity\"]","importance":60},{"ts":"2026-04-27","kind":"sec.filing","form_type":"6-K","title":"6-K — NOVO NORDISK A S — 2026-04-27","url_slug":"/sec/cik-0000353278/6-k/0001171843-26-002719","accession_number":"0001171843-26-002719","importance":30},{"ts":"2026-04-27","kind":"clinical.trial","reporter":"Novo Nordisk A/S","title":"A Research Study Looking at How NNC0487-0111 Affects Food Intake, Appetite and Metabolism After Meals in People With Obesity","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT07508020","excerpt":"[\"Obesity\"]","importance":30},{"ts":"2026-04-24","kind":"clinical.trial","reporter":"Novo Nordisk A/S","title":"A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow","security_title":"PHASE3","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT05330325","excerpt":"[\"SGA, Turner Syndrome, Noonan Syndrome, ISS\"]","importance":60},{"ts":"2026-04-24","kind":"clinical.trial","reporter":"Novo Nordisk A/S","title":"A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT06612268","excerpt":"[\"Sickle Cell Disease\"]","importance":60},{"ts":"2026-04-24","kind":"clinical.trial","reporter":"Novo Nordisk A/S","title":"A Research Study Looking Into How NNC0662-0419 Works With Birth Control Pills and Emptying of the Stomach in Women Not Able to Become Pregnant With Excess Body Weight","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT07525791","excerpt":"[\"Overweight\",\"Obesity\"]","importance":30},{"ts":"2026-04-23","kind":"clinical.trial","reporter":"Novo Nordisk A/S","title":"A Research Study to See How Semaglutide Helps People With Excess Weight, Lose Weight (STEP UP)","security_title":"PHASE3","status":"COMPLETED","accession_number":"NCT05646706","excerpt":"[\"Obesity\"]","importance":70},{"ts":"2026-04-22","kind":"clinical.trial","reporter":"Novo Nordisk A/S","title":"A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor","security_title":"PHASE3","status":"COMPLETED","accession_number":"NCT06221969","excerpt":"[\"Type 2 Diabetes\"]","importance":70},{"ts":"2026-04-21","kind":"clinical.trial","reporter":"Novo Nordisk A/S","title":"Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide","security_title":"PHASE3","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT07220759","excerpt":"[\"Overweight\",\"Obesity\",\"Type 2 Diabetes\"]","importance":60},{"ts":"2026-04-21","kind":"clinical.trial","reporter":"Novo Nordisk A/S","title":"A Research Study on How Well Different Doses of the Medicine UBT251 Help People Living With Overweight or Obesity","security_title":"PHASE2","status":"RECRUITING","accession_number":"NCT07395687","excerpt":"[\"Overweight\",\"Obesity\"]","importance":45},{"ts":"2026-04-17","kind":"clinical.trial","reporter":"Novo Nordisk A/S","title":"Research Study on Whether Semaglutide Works in People With Non-alcoholic Steatohepatitis (NASH)","security_title":"PHASE3","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT04822181","excerpt":"[\"Non-alcoholic Steatohepatitis\"]","importance":60},{"ts":"2026-04-14","kind":"clinical.trial","reporter":"Novo Nordisk A/S","title":"ARTEMIS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With a Heart Attack","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT06118281","excerpt":"[\"Cardiovascular Risk\",\"Acute Myocardial Infarction (AMI)\"]","importance":60},{"ts":"2026-04-13","kind":"clinical.trial","reporter":"Novo Nordisk A/S","title":"ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation","security_title":"PHASE3","status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT05021835","excerpt":"[\"Cardiovascular Risk\",\"Chronic Kidney Disease\",\"Inflammation\"]","importance":60},{"ts":"2026-04-13","kind":"clinical.trial","reporter":"Novo Nordisk A/S","title":"Post-Marketing Surveillance (Special Use-results Surveillance on Long-term Use) With Sogroya®","security_title":null,"status":"ACTIVE_NOT_RECRUITING","accession_number":"NCT05230550","excerpt":"[\"Adult Growth Hormone Deficiency\"]","importance":25},{"ts":"2026-04-13","kind":"clinical.trial","reporter":"Novo Nordisk A/S","title":"Timely Detection of Treatment Emergent Serious and Non-serious Adverse Events for Saxenda® in Mexican Patients","security_title":null,"status":"COMPLETED","accession_number":"NCT02773355","excerpt":"[\"Obesity\"]","importance":25},{"ts":"2026-04-09","kind":"clinical.trial","reporter":"Novo Nordisk A/S","title":"A Research Study to See How a New Weekly Insulin, Insulin Icodec When Given Along With Semaglutide Helps in Reducing the Blood Sugar Level in Patients With Type 2 Diabetes","security_title":"PHASE3","status":"COMPLETED","accession_number":"NCT05813912","excerpt":"[\"Diabetes Mellitus, Type 2\"]","importance":70},{"ts":"2026-04-09","kind":"clinical.trial","reporter":"Novo Nordisk A/S","title":"A Research Study Looking at How Well a Combination of the Medicines Semaglutide and NNC0480-0389 Works in People With Type 2 Diabetes","security_title":"PHASE2","status":"COMPLETED","accession_number":"NCT05144984","excerpt":"[\"Diabetes Mellitus, Type 2\"]","importance":45},{"ts":"2026-04-09","kind":"clinical.trial","reporter":"Novo Nordisk A/S","title":"A Study to Test How New Long-acting Insulin (Insulin Icodec) Works in the Body of Children and Teenagers","security_title":"PHASE1","status":"COMPLETED","accession_number":"NCT05790681","excerpt":"[\"Diabetes Mellitus, Type 2\"]","importance":30},{"ts":"2026-04-09","kind":"clinical.trial","reporter":"Novo Nordisk A/S","title":"A Research Study of a New Medicine NNC0363-1063 in Healthy Participants and Participants With Type 1 Diabetes","security_title":"PHASE1","status":"COMPLETED","accession_number":"NCT06685185","excerpt":"[\"Diabetes Mellitus, Type 1\"]","importance":30},{"ts":"2026-04-09","kind":"clinical.trial","reporter":"Novo Nordisk A/S","title":"User Experience With DuraTouch® in Patients With Type 1 or Type 2 Diabetes","security_title":null,"status":"COMPLETED","accession_number":"NCT07052292","excerpt":"[\"Diabetes Mellitus, Type 1\",\"Diabetes Mellitus, Type 2\"]","importance":25},{"ts":"2026-04-09","kind":"clinical.trial","reporter":"Novo Nordisk A/S","title":"General Use-results Surveillance With Awiqli in Patients With Diabetes Mellitus","security_title":null,"status":"RECRUITING","accession_number":"NCT06807190","excerpt":"[\"Diabetes Mellitus, Type 1\"]","importance":25},{"ts":"2026-04-09","kind":"clinical.trial","reporter":"Novo Nordisk A/S","title":"An Indian Post Marketing Study of Mealtime Insulin, Fiasp®, to Evaluate Its Safety and Effectiveness in Patients With Diabetes Mellitus in Routine Clinical Practice","security_title":null,"status":"COMPLETED","accession_number":"NCT03987802","excerpt":"[\"Diabetes Mellitus, Type 1\",\"Diabetes Mellitus, Type 2\"]","importance":25},{"ts":"2026-04-08","kind":"clinical.trial","reporter":"Novo Nordisk A/S","title":"Study of the Effect of Etavopivat on Cerebral Hemodynamic Response in Children With Sickle Cell Disease","security_title":"PHASE2","status":"COMPLETED","accession_number":"NCT05725902","excerpt":"[\"Sickle Cell Disease\"]","importance":45},{"ts":"2026-04-08","kind":"clinical.trial","reporter":"Novo Nordisk A/S","title":"Prevalence of Weight Related Complications Across Diverse Weight Classifications - A Large Study in India, Pakistan, Philippines and Vietnam","security_title":null,"status":"COMPLETED","accession_number":"NCT06843473","excerpt":"[\"Obesity\",\"Obesity-related Complications\"]","importance":25},{"ts":"2026-04-07","kind":"clinical.trial","reporter":"Novo Nordisk A/S","title":"A Research Study Looking Into How Ziltivekimab Works Compared to Placebo in Participants With Heart Failure and Inflammation","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT06200207","excerpt":"[\"Heart Failure\",\"Systemic Inflammation\"]","importance":60},{"ts":"2026-04-07","kind":"clinical.trial","reporter":"Novo Nordisk A/S","title":"Multiple Dose Study for a New Medication to Potentially Treat Liver Diseases","security_title":"PHASE1","status":"RECRUITING","accession_number":"NCT06891365","excerpt":"[\"Healthy Volunteers\",\"Hepatic Steatosis\"]","importance":30},{"ts":"2026-04-07","kind":"clinical.trial","reporter":"Novo Nordisk A/S","title":"A Research Study Looking Into Blood Levels of the Medicine NNC0519-0130 in the Body in Participants With Normal or Reduced Kidney Function","security_title":"PHASE1","status":"COMPLETED","accession_number":"NCT06370819","excerpt":"[\"Diabetes Mellitus, Type 2\"]","importance":30},{"ts":"2026-04-07","kind":"clinical.trial","reporter":"Novo Nordisk A/S","title":"A Study to Test How Insulin NNC0471-0119 H Works in the Body in Participants With Type 2 Diabetes When Given by an Insulin Pump","security_title":"PHASE1","status":"COMPLETED","accession_number":"NCT07068295","excerpt":"[\"Diabetes Mellitus, Type 2\"]","importance":30},{"ts":"2026-04-06","kind":"clinical.trial","reporter":"Novo Nordisk A/S","title":"A Research Study to See How Insulin Icodec Helps People With Type 1 Diabetes Control Their Blood Sugar","security_title":null,"status":"RECRUITING","accession_number":"NCT07160816","excerpt":"[\"Diabetes Mellitus, Type 1\"]","importance":25},{"ts":"2026-04-06","kind":"clinical.trial","reporter":"Novo Nordisk A/S","title":"A Study to Follow Paediatric Participants With Growth Hormone Deficiency Treated With Somapacitan for Long Term Safety Information and Clinical Parameters","security_title":null,"status":"ENROLLING_BY_INVITATION","accession_number":"NCT06709040","excerpt":"[\"Growth Hormone Deficiency\",\"Neoplasms\",\"Diabetes Mellitus Type 2\"]","importance":25},{"ts":"2026-04-06","kind":"clinical.trial","reporter":"Novo Nordisk A/S","title":"A Research Study to See How Well Weekly Insulin Icodec Maintains Blood Sugar Levels Compared to Daily Basal Insulins in Adults With Type 2 Diabetes","security_title":"PHASE4","status":"RECRUITING","accession_number":"NCT07112339","excerpt":"[\"Diabetes Mellitus, Type 2\"]","importance":25},{"ts":"2026-04-03","kind":"clinical.trial","reporter":"Novo Nordisk A/S","title":"A Research Study Comparing Different Ways of Increasing the Dose of NNC0519-0130 in Participants With Overweight or Obesity","security_title":"PHASE1","status":"COMPLETED","accession_number":"NCT06718998","excerpt":"[\"Obesity\"]","importance":30},{"ts":"2026-04-02","kind":"clinical.trial","reporter":"Novo Nordisk A/S","title":"A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight","security_title":"PHASE3","status":"RECRUITING","accession_number":"NCT07253285","excerpt":"[\"Overweight\",\"Obesity\"]","importance":60},{"ts":"2026-04-01","kind":"clinical.trial","reporter":"Novo Nordisk A/S","title":"A Research Study to See if Kidney Damage in People With Chronic Kidney Disease and Type 2 Diabetes Living With Overweight or Obesity Can be Reduced by CagriSema Compared to Semaglutide, Cagrilintide and Placebo","security_title":"PHASE2","status":"COMPLETED","accession_number":"NCT06131372","excerpt":"[\"Chronic Kidney Disease\",\"Type 2 Diabetes\",\"Obesity\"]","importance":45},{"ts":"2026-04-01","kind":"clinical.trial","reporter":"Novo Nordisk A/S","title":"A Study Looking at How Different Doses of Study Medicine (Inno8) Works in the Body of Healthy Men","security_title":"PHASE1","status":"COMPLETED","accession_number":"NCT06649630","excerpt":"[\"Haemophilia A\"]","importance":30},{"ts":"2026-03-31","kind":"clinical.trial","reporter":"Novo Nordisk A/S","title":"A Research Study of the New Medicine NNC0519-0130 in Male Chinese Participants Living With Excess Body Weight","security_title":"PHASE1","status":"COMPLETED","accession_number":"NCT07004322","excerpt":"[\"Diabetes Mellitus, Type 2\",\"Obesity\"]","importance":30},{"ts":"2026-03-30","kind":"clinical.trial","reporter":"Novo Nordisk A/S","title":"A Research Study to Compare Two Different Versions of Injectable CagriSema in People With Type 2 Diabetes","security_title":"PHASE2","status":"NOT_YET_RECRUITING","accession_number":"NCT07357740","excerpt":"[\"Diabetes Mellitus, Type 2\"]","importance":45},{"ts":"2026-03-27","kind":"clinical.trial","reporter":"Novo Nordisk A/S","title":"A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)","security_title":"PHASE3","status":"COMPLETED","accession_number":"NCT04777409","excerpt":"[\"Early Alzheimer\\u00b4s Disease\"]","importance":70},{"ts":"2026-03-27","kind":"clinical.trial","reporter":"Novo Nordisk A/S","title":"A Research Study to See How Safe is Eptacog Alfa When Used to Stop Heavy Bleeding in Women After Giving Birth in India","security_title":"PHASE4","status":"RECRUITING","accession_number":"NCT07157423","excerpt":"[\"Severe Postpartum Haemorrhage\"]","importance":25}]}